Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05447325 · ClinicalTrials.gov registry record · NA

Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users

A NA study of Message Exposure (Sequence: Regular Then Flavor) and Message Exposure (Sequence: Flavor Then Regular), sponsored by University of Georgia.

Recruiting
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT05447325: Recruiting NA study of Message Exposure (Sequence: Regular Then Flavor) and Message Exposure (Sequence: Flavor Then Regular), sponsored by University of Georgia.

NCT05447325 is a NA study of Message Exposure (Sequence: Regular Then Flavor) and Message Exposure (Sequence: Flavor Then Regular) that is actively recruiting participants, run by University of Georgia. The registered enrollment target is 180 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05447325, a NA study of Message Exposure (Sequence: Regular Then Flavor) and Message Exposure (Sequence: Flavor Then Regular), is actively recruiting participants, sponsored by University of Georgia.

RECRUITING
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

180 young adult vapers who are not current smokers will participate in a baseline functional magnetic resonance imaging (fMRI) experiment, prospectively linked to a 1-year randomized controlled trial. Baseline fMRI tasks will probe critical neurocognitive markers with high potential to account for individual differences in nicotine use prognosis and responsiveness to anti-vaping public service announcements (PSAs). Participants will be assigned randomly to a survey-only control condition, or one of two intervention orders, Regular PSA then Flavor PSA, and Flavor PSA then Regular PSA (n=60 each) in a 1-year counterbalanced crossover design. Every week intervention groups will receive anti-vaping PSAs either do not specifically address harms associated with vaping flavors (regular PSAs) or PSAs with a theme focusing on the harms of flavored vape products (flavor PSAs). Participants of the intervention groups will switch PSA exposure condition after 6 months. Their evaluations of the PSAs will be assessed with brief weekly online surveys. The links to the weekly online surveys will be sent via e-mail and text which allow them to access the surveys using any device with an internet browser. During the survey, the PSA of that week will first be displayed to PSA groups (n=120), followed by a query to provide message evaluation. Afterward, the survey questions will also assess their e-cigarette, cigarette, other tobacco use, and nicotine dependence, during the past week. The control group (n=60) will complete the surveys without viewing PSAs. In-person assessments at 3, 6, 9, and 12 months will biochemically confirm nicotine exposure.

Primary Outcome

The monthly number of cigarettes smoked will be assessed with the timeline follow-back measures. Specifically, participants will be asked to retrospectively estimate their daily cigarette use for the 7 days prior to the weekly survey date. The four weekly estimates will be averaged to create the monthly smoking severity measure. The greater the number, the higher the smoking severity in that month.

Interventions

  • BEHAVIORAL Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes)
  • BEHAVIORAL Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes)
  • BEHAVIORAL Exposure to Anti-Vaping Messages (no message exposure)

Study Locations (1)

Georgia

  • UGA Bio-imaging Research Center - Athens

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2022-07-15
Est. Completion 2026-07-31
Phase NA
University of Georgia

59 total trials

What NCT05447325 shows while recruiting

NCT05447325 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).

The record links to 3 conditions, with Message Exposure (Sequence: Regular Then Flavor) appearing as the primary indexed condition, and to 3 interventions - of which Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes) is the first listed.

NCT05447325 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT05447325 about?

NCT05447325 is a clinical study titled "Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users". 180 young adult vapers who are not current smokers will participate in a baseline functional magnetic resonance imaging (fMRI) experiment, prospectively linked to a 1-year randomized controlled trial. Baseline fMRI tasks will probe critical neurocognitive markers with high potential to account for i...

What is the current status of trial NCT05447325?

This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2022-07-15. Estimated completion is 2026-07-31.

What conditions does trial NCT05447325 study?

This clinical trial studies the following conditions: Message Exposure (Sequence: Regular Then Flavor), Message Exposure (Sequence: Flavor Then Regular), No Message Exposure (Control Condition).

What interventions are being tested in trial NCT05447325?

The interventions under investigation include: Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes) (BEHAVIORAL), Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes) (BEHAVIORAL), Exposure to Anti-Vaping Messages (no message exposure) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05447325?

This trial is sponsored by University of Georgia, which has 59 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05447325 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT05447325's enrollment target sits among peer trials

180 586th of 2000 higher than 1,397 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05447325, the US trial registry maintained by the National Library of Medicine. NCT05447325 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.